Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

An online fundraising appeal for coronavirus (COVID-19) research at Oxford has raised more than £50,000 from over 200 individuals after launching just two weeks ago. The donations will be deployed immediately, boosting projects ranging from vaccine development to the delivery of new drugs to treat the virus.

This transmission electron microscope image shows SARS-CoV-2, isolated from a patient in the U.S., emerging from the surface of cells cultured in the lab © NIAID-RML
This transmission electron microscope image shows SARS-CoV-2, isolated from a patient in the U.S., emerging from the surface of cells cultured in the lab

The University is at the forefront of global efforts to understand and control the coronavirus pandemic, with around 90 principal investigators and 1,300 researchers, post-docs and students working around the clock to develop effective vaccines, drugs and public health measures.

Oxford is in a unique position to tackle the pandemic, but access to flexible funding is essential. Donations of all sizes will have an immediate impact on the University’s response to the crisis, filling gaps in funding to ensure that clinical trials can continue, that supply lines keep moving, and that researchers are able to work at both speed and scale.

Read the full story on the University of Oxford Development Office website

Update (16.04.20): The fundraising appeal has now raised a fanastic £85,000 - and counting!

Similar stories

Study reveals ‘stop-eating’ response to DNA damage

A new study from the MRC Weatherall Institute of Molecular Medicine sheds light on the mechanism by which DNA damage suppresses appetite, a finding with implications for understanding the appetite lowering side-effects of chemotherapy.

Fiona Powrie appointed new Deputy Chair of Wellcome’s Board of Governors

Fiona Powrie, Director of the Kennedy Institute of Rheumatology at the University of Oxford has been selected as the next Deputy Chair of Wellcome’s Board of Governors.

World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition

Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.

One high altitude explorer acknowledges another

NASA Astronaut and Physiologist Dr Jessica Meir unveils The Physiological Society blue plaque in honour of fellow pioneering Physiologist and Scientific Explorer Mabel FitzGerald.

Oxford-led research maps milestone stage of human development for the first time

Scientists have shed light on an important stage of early embryonic development that has never been fully mapped out in humans before.